Rozanolixizumab's EU approval for self-administration methods aims to improve patient autonomy and satisfaction by minimizing clinic visits. The phase 3 MG0020 study confirmed the safety and efficacy ...
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback